These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 33087511)

  • 1. Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer.
    Dees S; Ganesan R; Singh S; Grewal IS
    Mol Cancer Ther; 2020 Dec; 19(12):2409-2421. PubMed ID: 33087511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil.
    Nasiri F; Kazemi M; Mirarefin SMJ; Mahboubi Kancha M; Ahmadi Najafabadi M; Salem F; Dashti Shokoohi S; Evazi Bakhshi S; Safarzadeh Kozani P; Safarzadeh Kozani P
    Front Immunol; 2022; 13():1018786. PubMed ID: 36483567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.
    Zhou R; Yazdanifar M; Roy LD; Whilding LM; Gavrill A; Maher J; Mukherjee P
    Front Immunol; 2019; 10():1149. PubMed ID: 31178870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer.
    Wei H; Wang Z; Kuang Y; Wu Z; Zhao S; Zhang Z; Li H; Zheng M; Zhang N; Long C; Guo W; Nie C; Yang H; Tong A
    Front Immunol; 2020; 11():573823. PubMed ID: 33072116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies.
    Niu Z; Wu J; Zhao Q; Zhang J; Zhang P; Yang Y
    Front Immunol; 2024; 15():1385571. PubMed ID: 38680498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of CD22 in Triple-Negative Breast Cancer: A Novel Prognostic Biomarker and Potential Target for CAR Therapy.
    Zaib T; Cheng K; Liu T; Mei R; Liu Q; Zhou X; He L; Rashid H; Xie Q; Khan H; Xu Y; Sun P; Wu J
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging Immunotherapies against Novel Molecular Targets in Breast Cancer.
    Sivaganesh V; Promi N; Maher S; Peethambaran B
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33670942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spatiotemporal PET Imaging Reveals Differences in CAR-T Tumor Retention in Triple-Negative Breast Cancer Models.
    Volpe A; Lang C; Lim L; Man F; Kurtys E; Ashmore-Harris C; Johnson P; Skourti E; de Rosales RTM; Fruhwirth GO
    Mol Ther; 2020 Oct; 28(10):2271-2285. PubMed ID: 32645298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers.
    Wei J; Sun H; Zhang A; Wu X; Li Y; Liu J; Duan Y; Xiao F; Wang H; Lv M; Wang L; Wu C
    Cell Immunol; 2018 Sep; 331():49-58. PubMed ID: 29935762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
    Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
    Front Oncol; 2022; 12():919072. PubMed ID: 35795050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level.
    Song DG; Ye Q; Poussin M; Chacon JA; Figini M; Powell DJ
    J Hematol Oncol; 2016 Jul; 9(1):56. PubMed ID: 27439908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress.
    Corti C; Venetis K; Sajjadi E; Zattoni L; Curigliano G; Fusco N
    Expert Opin Investig Drugs; 2022 Jun; 31(6):593-605. PubMed ID: 35311430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in triple-negative breast cancer.
    Katz H; Alsharedi M
    Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
    Dalenc F; Sarradin V; Nicolaï V; Franchet C; Ung M
    Bull Cancer; 2021 Jan; 108(1):67-79. PubMed ID: 33422340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel chimeric antigen receptor T cell-based immunotherapy: a perspective for triple-negative breast cancer.
    Geng P; Chi Y; Yuan Y; Yang M; Zhao X; Liu Z; Liu G; Liu Y; Zhu L; Wang S
    Front Cell Dev Biol; 2023; 11():1158539. PubMed ID: 37457288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapeutic interventions of Triple Negative Breast Cancer.
    Li Z; Qiu Y; Lu W; Jiang Y; Wang J
    J Transl Med; 2018 May; 16(1):147. PubMed ID: 29848327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer.
    Byrd TT; Fousek K; Pignata A; Szot C; Samaha H; Seaman S; Dobrolecki L; Salsman VS; Oo HZ; Bielamowicz K; Landi D; Rainusso N; Hicks J; Powell S; Baker ML; Wels WS; Koch J; Sorensen PH; Deneen B; Ellis MJ; Lewis MT; Hegde M; Fletcher BS; St Croix B; Ahmed N
    Cancer Res; 2018 Jan; 78(2):489-500. PubMed ID: 29183891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.
    Han Y; Xie W; Song DG; Powell DJ
    J Hematol Oncol; 2018 Jul; 11(1):92. PubMed ID: 29980239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
    Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
    Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.